Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference being held in New York, NY on September 12-14, 2022.
Edesa Presentation Details
Date: September 12, 2022
Time: 10:00 am Eastern Time
Presentation Slides: Available in the events section of the Edesa website.
Attendees who are interested in meeting with the company should contact their H.C. Wainwright representative or Edesa directly via email at This email address is being protected from spambots. You need JavaScript enabled to view it..
About Edesa Biotech, Inc.
Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that Edesa is developing as a treatment for Acute Respiratory Distress Syndrome (ARDS). Edesa is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. Sign up for news alerts. Connect with Edesa Biotech on Twitter and LinkedIn.
Contact
Gary Koppenjan
Edesa Biotech, Inc.
(805) 488-2800 ext. 150
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.14 |
| Daily Change: | -0.11 -4.89 |
| Daily Volume: | 25,334 |
| Market Cap: | US$15.020M |
February 14, 2025 February 13, 2025 December 13, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
